Year None20202019201820172016 Date Latest Press Release November 23, 2020 Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million November 20, 2020 Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies November 17, 2020 Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience™ 2020 November 16, 2020 Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience™ 2020 November 11, 2020 Eiger Bio to Participate in November 2020 Investor Conferences November 5, 2020 Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update November 2, 2020 Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience™ 2020 October 15, 2020 Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19 September 28, 2020 Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19 September 1, 2020 Eiger Bio to Participate in September 2020 Investor Conferences Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
